Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05945888
PHASE1

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The single rising dose (SRD) part of the trial investigates safety, tolerability, and pharmacokinetics of BI 3000202. The food effect (FE) part is conducted to assess the effect of food on the relative bioavailability of the BI 3000202 formulation.

Official title: A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3000202 Administered as Tablet to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Relative Bioavailability Comparison of BI 3000202 as Tablet With and Without Food in Healthy Male Subjects

Key Details

Gender

MALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

68

Start Date

2023-07-25

Completion Date

2023-11-13

Last Updated

2026-06-08

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

BI 3000202

BI 3000202

DRUG

Placebo matching BI 3000202

Placebo matching BI 3000202

Locations (1)

Humanpharmakologisches Zentrum Biberach

Biberach, Germany